CSF3 and neutropenia: Hence, in light of the well documented lower survival in patients who were treated with RDI < 85% [29, 31, 43–46, 55], in particular, due to neutropenia, an appropriate treatment or prophylactic G-CSF or antibiotic therapy should be given to the patients at the highest risk of neutropenia based on pretreatment ANC.